Pharvaris N.V (PHVS) | Financial Analysis & Statements
Pharvaris N.V. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-47.6M
Net Income
-46.7M
Balance Sheet Metrics
Total Assets
301.5M
Total Liabilities
30.2M
Shareholders Equity
271.3M
Debt to Equity
0.11
Cash Flow Metrics
Operating Cash Flow
-40.7M
Free Cash Flow
-38.0M
Revenue & Profitability Trend
Pharvaris N.V Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 124.5M | 98.6M | 65.6M | 57.4M | 35.8M |
| Selling, General & Administrative | 45.3M | 47.1M | 31.3M | 29.3M | 18.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 169.8M | 145.7M | 96.9M | 86.7M | 54.1M |
| Operating Income | -169.8M | -145.7M | -96.9M | -86.7M | -54.1M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | 16.1K | 267.5K |
| Other Non-Operating Income | -10.3M | 7.9M | -3.1M | 11.1M | 11.8M |
| Pre-tax Income | -173.7M | -132.4M | -99.8M | -75.7M | -42.7M |
| Income Tax | 2.0M | 1.8M | 1.0M | 679.1K | 70.1K |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -175.7M | -134.2M | -100.9M | -76.3M | -42.7M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -159.2M | -153.3M | -93.5M | -97.7M | -65.8M |
| EPS (Basic) | $-2.97 | $-2.48 | $-2.63 | $-2.27 | $-1.40 |
| EPS (Diluted) | $-2.97 | $-2.48 | $-2.63 | $-2.27 | $-1.40 |
| Basic Shares Outstanding | 59159247 | 54020549 | 34986122 | 32759089 | 29663160 |
| Diluted Shares Outstanding | 59159247 | 54020549 | 34986122 | 32759089 | 29663160 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Pharvaris N.V Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 291.7M | 280.7M | 391.2M | 161.8M | 209.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | 0 | 8.5K |
| Inventory | - | - | - | - | - |
| Other Current Assets | - | - | 620.8K | 582.6K | 5.7K |
| Total Current Assets | 299.2M | 289.4M | 397.9M | 166.8M | 211.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.8M | 1.7M | 580.9K | 692.0K | 378.0K |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 887.4K | 474.3K | 387.5K | 259.8K | 172.1K |
| Total Non-Current Assets | 2.3M | 2.0M | 843.1K | 886.2K | 523.4K |
| Total Assets | 301.5M | 291.4M | 398.7M | 167.7M | 212.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.1M | 4.6M | 2.9M | 6.0M | 2.1M |
| Short-term Debt | 200.2K | 222.4K | 195.3K | 187.4K | 99.4K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 29.6M | 23.0M | 14.6M | 18.2M | 7.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 576.6K | 639.0K | 43.6K | 249.4K | 150.8K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | -1 |
| Total Non-Current Liabilities | 576.6K | 639.0K | 43.6K | 249.4K | 150.8K |
| Total Liabilities | 30.2M | 23.6M | 14.6M | 18.5M | 7.1M |
| Equity | |||||
| Common Stock | 7.8M | 6.5M | 6.3M | 4.1M | 4.0M |
| Retained Earnings | -579.6M | -402.3M | -265.9M | -164.2M | -87.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 271.3M | 267.8M | 384.0M | 149.3M | 205.0M |
| Key Metrics | |||||
| Total Debt | 776.8K | 861.5K | 238.9K | 436.8K | 250.2K |
| Working Capital | 269.6M | 266.4M | 383.2M | 148.6M | 204.6M |
Balance Sheet Composition
Pharvaris N.V Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -173.7M | -132.4M | -99.8M | -75.7M | -42.7M |
| Depreciation & Amortization | 418.4K | 269.6K | 257.6K | 152.9K | 77.4K |
| Stock-Based Compensation | 19.1M | 16.2M | 10.7M | 11.3M | 8.2M |
| Working Capital Changes | 1.4M | -170.7K | -994.9K | -2.2M | 109.4K |
| Operating Cash Flow | -153.3M | -121.5M | -90.1M | -66.3M | -34.0M |
| Investing Activities | |||||
| Capital Expenditures | -164.6K | -538.1K | -90.0K | -124.3K | -130.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -164.6K | -538.1K | -90.0K | -124.3K | -130.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -219.0K | -159.7K | -220.5K | -119.5K | 0 |
| Financing Cash Flow | 160.6M | 2.7M | 325.4M | 8.7M | 143.7M |
| Free Cash Flow | -137.2M | -120.7M | -93.1M | -67.3M | -44.7M |
| Net Change in Cash | 7.2M | -119.4M | 235.2M | -57.8M | 109.5M |
Cash Flow Trend
Pharvaris N.V Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-9.17
Forward P/E
-9.60
Price to Book
6.15
PEG Ratio
-9.60
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-65.19%
Return on Assets
-35.81%
Financial Health
Current Ratio
10.11
Debt to Equity
0.29
Beta
-2.58
Per Share Data
EPS (TTM)
$-3.50
Book Value per Share
$4.89
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PHVS | 1.8B | -9.17 | 6.15 | -65.19% | 0.00% | 0.29 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Recursion | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
Financial data is updated regularly. All figures are in the company's reporting currency.






